argenx NV ADR share price logo

argenx NV ADR

NASDAQ: ARGX

Large Cap

$802.70

-10.11

(-1.24%)

as on

argenx NV ADR Stock Performance

as on May 14, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $789.99
    $810.70
    downward going graph

    1.58%

    Downside

    1.00%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $510.06
    $934.62
    downward going graph

    36.46%

    Downside

    16.43%

    Upside

    downward going graph

argenx NV ADR share price movements today

Previous Close
$812.81
Open
$797.52
Volume
357.5K
Day's Low - High
$789.99 - $810.70
52 Week Low - High
$510.06 - $934.62

argenx NV ADR Historical Returns

1 Month Return
-1.88 %
3 Month Return
-1.11 %
1 Year Return
+ 52.71 %
3 Year Return
+ 101.45 %
5 Year Return
+ 198.5 %

argenx NV ADR Stock Fundamentals & Key Indicators

Check argenx NV ADR market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$50.8B

EPS (TTM)

21.9627

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.14%

PE Ratio (TTM)

36.08

Industry PE ratio

-5.400434782608696

PEG Ratio

1.2513

EBITDA

1.3B

Revenue (TTM)

4.7B

Profit Margin

31.40%

Return On Equity TTM

20.15%

argenx NV ADR Stock Valuation

Track how argenx NV ADR P/E has moved over time to understand its valuation trends.

argenx NV ADR in the last 5 years

  • Overview

  • Trends

Lowest (-112.45x)

September 30, 2023

Industry (-5.40x)

May 14, 2026

Today (36.08x)

May 14, 2026

Highest (130.78x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 36.08x

argenx NV ADR vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of argenx NV ADR with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
argenx NV ADR image
argenx NV ADR
BUY$50.8B198.5%36.0831.40%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$38.0B115.2%71.3912.55%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.7BNA71.448.94%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.4B106.5%25.8435.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.7B40.03%17.3929.65%

Stock Returns calculator for argenx NV ADR Stock including INR - Dollar returns

The argenx NV ADR stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

argenx NV ADR investment value today

Current value as on today

₹1,69,253

Returns

₹69,253

(+69.25%)

Returns from argenx NV ADR Stock

₹50,807 (+50.81%)

Dollar Impact

₹18,446 (+18.45%)

Analyst Recommendation on argenx NV ADR Stock

Based on 25 analysts

BUY

72.00%

Buy

24.00%

Hold

4.00%

Sell

Based on 25 analysts, 72% of analysts recommend a 'BUY' rating for argenx NV ADR. Average target price of $1032.52

argenx NV ADR Share Price Target

Get share price movements and forecasts by analysts on argenx NV ADR.

What analysts predicted

22.26%UPSIDE

Target Price

$1032.52

Current Price

$802.7

Analyzed by

25 Analysts

Target

$1032.52

argenx NV ADR target price $1032.52, a slight upside of 22.26% compared to current price of $802.7. According to 25 analysts rating.

Indian Investors' Interest in argenx NV ADR Stock

Search interest for argenx NV ADR Stock has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:25% versus previous 30 day period

argenx NV ADR Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
826
401
970
636
1,346
790
947
1,126
2,406
1,298
Gross Profit
200
357
1,379
570
681
709
837
1,017
2,147
1,177
Operating Income
-219
-93
-138
14
117
138
201
349
658
394
EBITDA
-38
-73
-21
88
126
203
513
-
789
-
Interest Expense
0
0
0
0
0
1
1
0
1
1
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-144
-74
-89
88
174
202
286
386
787
426
Income Tax Expense
27
-12
-56
-3
-687
32
41
-
-87
-
Net Income
-169
-61
-35
101
865
169
245
344
874
366
Net Profit Margin
-20.54%
-15.36%
-3.61%
15.95%
64.29%
21.43%
25.88%
30.55%
36.36%
28.20%

argenx NV ADR Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
16
51
27
87
50
562
434
1,337
2,190
4,153
Gross Profit
16
51
27
87
50
562
403
1,209
1,962
3,702
Operating Income
-22
-27
-93
-198
-477
-348
-720
-425
-21
1,054
EBITDA
-22
-32
-93
-173
-601
-392
-622
-192
105
1,310
Interest Expense
-
5
35
0
0
1
2
0
2
4
Depreciation
-
0
0
2
3
5
104
111
17
28
Income Before Tax
-22
-32
-75
-175
-605
-399
-729
-304
85
1,278
Income Tax Expense
0
0
0
5
3
8
-19
-9
-747
-13
Net Income
-23
-39
-86
-201
-740
-460
-750
-321
833
1,292
Net Profit Margin
-145.27%
-77.10%
-310.22%
-230.95%
-1475.29%
-81.97%
-172.76%
-24.06%
38.03%
31.11%

argenx NV ADR Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-57
-32
84
865
149
418
295
874
366
Operating Cash Flow
-
-124
-
41
-
437
-
407
-
Investing Cash Flow
-
-513
-
-203
-
-10
-
829
-
Financing Cash Flow
-
40
-
239
-
74
-
158
-
Change in Cash
-
-610
-
61
-
586
-
1,405
-

argenx NV ADR Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-27
-93
-198
-477
-348
-720
-425
833
1,296
Operating Cash Flow
-43
-61
151
-398
-606
-862
-420
-82
850
Investing Cash Flow
-194
-123
-833
344
-347
-461
308
-717
823
Financing Cash Flow
366
279
733
833
1,119
843
1,336
279
233
Change in Cash
121
103
50
844
117
-533
1,248
-548
1,991

Mutual Funds that own argenx NV ADR Stock

Check out the Mutual Funds with significant holdings in argenx NV ADR.

Global Institutional Holdings in argenx NV ADR

Funds
Holdings
CI Private Wealth LLC
0.4%
T. Rowe Price Associates, Inc.
5.41%
Jennison Associates LLC
0.37%
Bellevue Group AG
0.74%
AllianceBernstein L.P.
0.67%
See all

argenx NV ADR News & Key Events

  • img

    Today's Timeline - 26 February

    Thu, 06:09 PM

    -

    Argenx reports strong 2025 results, achieving $4.15 billion in global product net sales and first profitable year.

Insights on argenx NV ADR

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ARGX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ARGX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ARGX stock has moved up by 3.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Argenx SE has seen a decline in its net profit over the last two quarters. The net profit dropped from $874.91 million to $366.0 million, reflecting an average decrease of 58.2% each quarter.

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    argenx SE has experienced a decline in revenue over the last two quarters. Revenue dropped from $2.40 billion to $1.29 billion, marking an average decrease of 46.1% per quarter.

About argenx NV ADR

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Organisationargenx NV ADR
HeadquartersLaarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB
IndustryBiotechnology
CEOMr. Karl Gubitz
E-voting on sharesClick here to vote

Key Management of argenx NV ADR

Name

Title

Dr. Luc Truyen

Chief Medical Officer

Mr. Marc Schorpion

Global Head of Human Resources

Mr. Achim Plueckebaum

Global Head of Digital Technologies

Ms. Sandrine Piret-Gerard

Chief Commercialization Officer

Dr. Peter Ulrichts

Chief Scientific Officer

Ms. Malini Moorthy

General Counsel & Corporate Secretary

Ms. Andria Wilk

Global Head of Quality

Mr. Karl Gubitz

Chief Financial Officer

Mr. Arjen Lemmen M.Sc.

Vice President of Corporate Development & Strategy

Mr. Filip Borgions

Chief Technology Innovation Officer

FAQs

What is argenx NV ADR share price today?

argenx NV ADR share price today is $802.7 as on at the close of the market. argenx NV ADR share today touched a day high of $810.7 and a low of $789.99.

What is the 52 week high and 52 week low for argenx NV ADR share?

argenx NV ADR share touched a 52 week high of $934.62 on and a 52 week low of $510.06 on . argenx NV ADR stock price today i.e. is closed at $802.7,which is 14.11% down from its 52 week high and 57.38% up from its 52 week low.

What is argenx NV ADR's market capitalisation today?

argenx NV ADR market capitalisation is $0.05T as on .

How to invest in argenx NV ADR Stock (ARGX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for argenx NV ADR on INDmoney app. Click on Buy button. You can invest as low as $1.5 in argenx NV ADR Shares that will get you 0.0019 shares as per argenx NV ADR share price of $802.7 per share as on May 14, 2026 at 8:46 am IST.

What is the minimum amount required to buy argenx NV ADR Stock (ARGX) from India?

Indian investors can start investing in argenx NV ADR (ARGX) shares with as little as ₹95.705 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in argenx NV ADR stock (as per the Rupee-Dollar exchange rate as on ). Based on argenx NV ADR share’s latest price of $802.7 as on May 14, 2026 at 8:46 am IST, you will get 0.0125 shares of argenx NV ADR. Learn more about fractional shares .

What are the returns that argenx NV ADR has given to Indian investors in the last 5 years?

argenx NV ADR stock has given 198.5% share price returns and 29.72% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?